Falcon Technologies Announces Its Participation and Attendance at the May 31, 2019 Food and Drug Administration Meeting for Products Containing Cannabis and Cannabis-Derived Compounds
Back to Newsroom
Mentioned in this Article

Falcon Technologies Announces Its Participation and Attendance at the May 31, 2019 Food and Drug Administration Meeting for Products Containing Cannabis and Cannabis-Derived Compounds

Wednesday, May 15, 2019 8:00 AM
Share this article now
Company Update

SACRAMENTO, CA / ACCESSWIRE / May 15, 2019 / Falcon Technologies, Inc. (OTC PINK: FLCN) announced today that a representative for Falcon Technologies, Inc. will be attending the May 31st Food and Drug Administration meeting for scientific data and information about products containing cannabis and cannabis-derived compounds.

Falcon Technologies is a public company focused on the marketing, sale, and distribution of CBD products and products derived from industrial hemp. According to the Food and Drug Administration, the goal of the hearing is to obtain additional scientific data and other information related to cannabis and cannabis-derived compounds, both from botanical and synthetic sources, to inform our regulatory oversight of these products. Falcon Technologies is proud to be a participant at this historic meeting of the United States Food and Drug Administration.

The Agriculture Improvement Act of 2018, Public Law 115-334 (the 2018 Farm Bill), which, among other things removed the plant Cannabis sativa L. or "hemp" from the Controlled Substances Act has dramatically increased the need for CBD science and and to educate the public on CBD products such as the ones Falcon are developing. The 2018 Farm Bill has also dramatically increased the demand for hemp-derived products. Falcon is 100 percent focused on the development, marketing and sale of CBD products and hemp-derived products.

Many of the participants at the FDA meeting will be leaders in the CBD industry, leading scientists, leading medical doctors and political heavyweights who have been instrumental in the legalization of the industrial hemp and the products derived from hemp including hemp protein, hemp oil and hemp seeds.

William J. Delgado, Chairman and Chief Executive Officer of Falcon Technologies stated, "We are excited Falcon will be represented at this very important meeting. The FDA understands the importance of CBD but also understands the importance of regulating CBD and other hemp-derived products."

CBD (Cannabidiol) is one of at least 80 active cannabinoids identified in both cannabis and industrial hemp. It is a major constituent of both plants, although the percentages of total composition can vary greatly from strain to strain. Unlike THC (the other prevalent cannabinoid), CBD is non-psychoactive while having the potential to possess a variety of therapeutic properties.

About Falcon Technologies, Inc. (a/k/a Eco-Growth Strategies, Inc.)

Falcon Technologies, Inc. (a/k/a Eco-Growth Strategies, Inc.) is a nutraceutical company developing a range of CBD-based products. The company's mission is to employ best practice science to source, manufacture and package all of its CBD products from within the United States. The company performs farm site visits and manufacturing site visits and sources its products from only the highest quality hemp farms and processors in North America. The company also aims to launch a line of CBD products specially formulated for animals by the end of 2019.

CBD Disclaimer

The statements made regarding CBD products including our future products have not been evaluated by the Food and Drug Administration. The efficacy of these products and the testimonials made have not been confirmed by FDA- approved research. These products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from health care practitioners. Please consult your healthcare professional about potential interactions or other possible complications before using any product. The Federal Food, Drug, and Cosmetic Act requires this notice.


Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: William J. Delgado

(775) 443-4740

[email protected]

SOURCE: Falcon Technologies

Falcon Technologies
Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions